Dan Zhou

Dr. Dan Zhou


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2024 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
DHDi He
Di He
ZWZhaoping Wang
Zhaoping Wang
JLJun Li
Jun Li
KYKaixin Yu
Kaixin Yu
YHYusa He
Yusa He
YZYimin Zhu
Yimin Zhu
Background and Aims: Previous studies found that frailty was an important risk factor for cardiovascular disease (CVD). However, previous studies only focused on baseline frailty status, not taking into consideration the changes in frailty status during follow-up. The aim of this study was to investigate the associations of changes in frailty status with incident CVD. Methods: This study used data of three prospective cohorts: China Health and Retirement Longitudinal Study (CHARLS), English Longitudinal Study of Ageing (ELSA), and Health and Retirement Study (HRS). Frailty status was evaluated by the Rockwood frailty index and classified as robust, pre-frail, or frail. Changes in frailty status were assessed by frailty status at baseline and the second survey which was two years after the baseline. Cardiovascular disease was ascertained by self-reported physician-diagnosed heart disease (including angina, heart attack, congestive heart failure, and other heart problems) or stroke. Cox proportional hazard models were used to calculate the hazard ratio (HR) and 95% confidence interval (95% CI) after adjusting for potential confounders. Results: A total of 7116 participants from CHARLS (female: 48.6%, mean age: 57.4 years), 5303 from ELSA (female: 57.7%, mean age: 63.7 years), and 7266 from HRS (female: 64.9%, mean age: 65.1 years) were included according to inclusion and exclusion criteria. The median follow-up periods were 5.0 years in the CHARLS, 10.7 years in the ELSA, and 9.5 years in the HRS. Compared with stable robust participants, robust participants who progressed to pre-frail or frail status had increased risks of incident CVD (CHARLS, HR = 1.84, 95% CI: 1.54–2.21; ELSA, HR = 1.53, 95% CI: 1.25–1.86; HRS, HR = 1.59, 95% CI: 1.31–1.92). In contrast, frail participants who recovered to robust or pre-frail status presented decreased risks of incident CVD (CHARLS, HR = 0.62, 95% CI: 0.47–0.81; ELSA, HR = 0.49, 95% CI: 0.34–0.69; HRS, HR = 0.70, 95% CI: 0.55–0.89) when compared with stable frail participants. These decreased risks of incident CVD were also observed in pre-frail participants who recovered to robust status (CHARLS, HR = 0.66, 95% CI: 0.52–0.83; ELSA, HR = 0.65, 95% CI: 0.49–0.85; HRS, HR = 0.71, 95% CI: 0.56–0.91) when compared with stable pre-frail participants. Conclusions: Different changes in frailty status are associated with different risks of incident CVD. Progression of frailty status increases incident CVD risks, while recovery of frailty status decreases incident CVD risks.

5 October 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DZDan Zhou
Dan Zhou
YJYi Jiang
Yi Jiang
XZXue Zhong
Xue Zhong
NCNancy J. Cox
Nancy J. Cox
CLCHUNYU LIU
CHUNYU LIU
EGEric Gamazon
Eric Gamazon

28 April 2023 in BMC Medicine
Verified
Journal Article
Open access
PDF file
JFJiayao Fan
Jiayao Fan
YZYuan Zhou
Yuan Zhou
RMRan Meng
Ran Meng
JTJinsong Tang
Jinsong Tang
JZJiahao Zhu
Jiahao Zhu
DZDan Zhou
Dan Zhou
Background: Considerable evidence has been reported that tobacco use could cause alterations in gut microbiota composition. The microbiota-gut–brain axis also in turn hinted at a possible contribution of the gut microbiota to smoking. However, population-level studies with a higher evidence level for causality are lacking. Methods: This study utilized the summary-level data of respective genome-wide association study (GWAS) for 211 gut microbial taxa and five smoking phenotypes to reveal the causal association between the gut microbiota and tobacco smoking. Two-sample bidirectional Mendelian randomization (MR) design was deployed and comprehensively sensitive analyses were followed to validate the robustness of results. We further performed multivariable MR to evaluate the effect of neurotransmitter-associated metabolites on observed associations. Results: Our univariable MR results confirmed the effects of smoking on three taxa (Intestinimonas, Catenibacterium, and Ruminococcaceae, observed from previous studies) with boosted evidence level and identified another 13 taxa which may be causally affected by tobacco smoking. As for the other direction, we revealed that smoking behaviors could be potential consequence of specific taxa abundance. Combining with existing observational evidence, we provided novel insights regarding a positive feedback loop of smoking through Actinobacteria and indicated a potential mechanism for the link between parental smoking and early smoking initiation of their children driven by Bifidobacterium. The multivariable MR results suggested that neurotransmitter-associated metabolites (tryptophan and tyrosine, also supported by previous studies) probably played a role in the action pathway from the gut microbiota to smoking, especially for Actinobacteria and Peptococcus. Conclusions: In summary, the current study suggested the role of the specific gut microbes on the risk for cigarette smoking (likely involving alterations in metabolites) and in turn smoking on specific gut microbes. Our findings highlighted the hazards of tobacco use for gut flora dysbiosis and shed light on the potential role of specific gut microbiota for smoking behaviors.

1 November 2022 in British Journal of Dermatology
Verified
Journal Article
Closed access
JWJiahe Wei
Jiahe Wei
JZJiahao Zhu
Jiahao Zhu
HXHuiqing Xu
Huiqing Xu
DZDan Zhou
Dan Zhou
JEJames T. Elder
James T. Elder
YLYingjun Li
Yingjun Li

20 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DZDan Zhou
Dan Zhou
DYDongmei Yu
Dongmei Yu
JSJeremiah M. Scharf
Jeremiah M. Scharf
CMCarol A. Mathews
Carol A. Mathews
LMLauren McGrath
Lauren McGrath
EGEric Gamazon
Eric Gamazon
Studies of the genetic basis of complex traits have demonstrated a substantial role for common, small-effect variant polygenic burden (PB) as well as large-effect variants (LEV, primarily rare). We identify sufficient conditions in which GWAS-derived PB may be used for well-powered rare pathogenic variant discovery or as a sample prioritization tool for whole-genome or exome sequencing. Through extensive simulations of genetic architectures and generative models of disease liability with parameters informed by empirical data, we quantify the power to detect, among cases, a lower PB in LEV carriers than in non-carriers. Furthermore, we uncover clinically useful conditions wherein the risk derived from the PB is comparable to the LEV-derived risk. The resulting summary-statistics-based methodology (with publicly available software, PB-LEV-SCAN) makes predictions on PB-based LEV screening for 36 complex traits, which we confirm in several disease datasets with available LEV information in the UK Biobank, with important implications on clinical decision-making.

13 December 2023 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
YSYanfa Sun
Yanfa Sun
JZJingjing Zhu
Jingjing Zhu
YYYaohua Yang
Yaohua Yang
ZZZichen Zhang
Zichen Zhang
HZHua Zhong
Hua Zhong
LWLang Wu
Lang Wu
Alzheimer disease (AD) is a common neurodegenerative disease with a late onset. It is critical to identify novel blood-based DNA methylation biomarkers to better understand the extent of the molecular pathways affected in AD. Two sets of blood DNA methylation genetic prediction models developed using different reference panels and modelling strategies were leveraged to evaluate associations of genetically predicted DNA methylation levels with AD risk in 111,326 (46,828 proxy) cases and 677,663 controls. A total of 1,168 cytosine-phosphate-guanine (CpG) sites showed a significant association with AD risk at a false discovery rate (FDR) < 0.05. Methylation levels of 196 CpG sites were correlated with expression levels of 130 adjacent genes in blood. Overall, 52 CpG sites of 32 genes showed consistent association directions for the methylation-gene expression-AD risk, including nine genes (CNIH4, THUMPD3, SERPINB9, MTUS1, CISD1, FRAT2, CCDC88B, FES, and SSH2) firstly reported as AD risk genes. Nine of 32 genes were enriched in dementia and AD disease categories (P values ranged from 1.85 × 10-4 to 7.46 × 10-6), and 19 genes in a neurological disease network (score = 54) were also observed. Our findings improve the understanding of genetics and etiology for AD.